A New Tool for the Lamb Shift Calculation

We solve the Bethe-Salpeter equation for hydrogenic bound states by choosing an appropriate interaction kernel $K_c$. We want to use our solution to calculate up to a higher order the hydrogen Lamb-shift, and as a first application we present up to order \left(\aa / \pi\right)(\za)^7 the contribution of the lowest order self-energy graph, calculated {\it exactly}. The basic formalism is a natural extension to the hydrogenic bound states of the one previously presented by R. Barbieri and E. Remiddi and used in the case of positronium.Comment: 21 pages, Latex, Preprint DFUB-94-0

Theory of intrinsic acoustic plasmons in twisted bilayer graphene

We present a theoretical study of the intrinsic plasmonic properties of twisted bilayer graphene (TBG) as a function of the twist angle θ (and other microscopic parameters such as temperature and filling factor). Our calculations, which rely on the random phase approximation, take into account four crucially important effects, which are treated on equal footing: i) the layer-pseudospin degree of freedom, ii) spatial non-locality of the density-density response function, iii) crystalline local field effects, and iv) Hartree self-consistency. We show that the plasmonic spectrum of TBG displays a smooth transition from a strongly-coupled regime (at twist angles θ . 2◦), where the low-energy spectrum is dominated by a weakly dispersive intra-band plasmon, to a weakly-coupled regime (for twist angles θ & 2◦) where an acoustic plasmon clearly emerges. This crossover offers the possibility of realizing tunable mid-infrared sub-wavelength cavities, whose vacuum fluctuations may be used to manipulate the ground state of strongly correlated electron systems

Endoscopic endonasal approach for loco-regional recurrent clivus chordomas

Introduction. Role of surgery for loco-regional recurrences of clivus chordomas (CCs) is still debated. It has been proposed in selected cases with a curative or with palliative intent, eventually followed by radiation or chemo/radiation treatments. Only limited data on the endoscopic endonasal approach (EEA) are available. Research question. To assess the role of EEA for loco-regional recurrent CCs. Materials and Methods. All consecutive loco-regional recurrent CCs operated by EEA at our Institution from 1998 to 2021 were identified. The extension of tumor resection, symptoms control, overall survival (OS), and progression free survival (PFS) were assessed. Results. Series includes 54 patients (53.7% females, mean age 55± 14 years). Surgery was planned with a resective aim in 35 (64.8%) patients, while it was palliative in 19 (35.2%). Gross tumor removal was achieved in 24 cases (44.4%). Main complications consisted of 2 (3.7%) CSF leaks. Further local relapses were observed in 30 (55.5%) patients after 25± 24 months; 29 (53.7%) patients deceased after 34 ± 31 months. OS and PFS were lower in these cases than primary surgeries (p<0.001 and p<0.001), but cases undergone surgery with a resective aim had a significant better OS and PFS than for those treated for palliation (p<0.001). Determinants of recurrences were tumoral size (p=0.48) and previous radiotherapy (p=009). Discussion and Conclusions. EEA has proven to be effective for loco-regional recurrent CCs alleviating patients symptoms and preserving their quality of life with limited morbidities. However, because overall prognosis is poor, EEA should be reserved to selected recurrent cases

The impact of the Hippo pathway and cell metabolism on pathological complete response in locally advanced Her2+ breast cancer: the TRISKELE multicenter prospective study

The Hippo pathway and its two key effectors, Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), are consistently altered in breast cancer. Pivotal regulators of cell metabolism such as the AMP-activated protein kinase (AMPK), Stearoyl-CoA-desaturase 1 (SCD1), and HMG-CoA reductase (HMGCR) are relevant modulators of TAZ/YAP activity. In this prospective study, we measured the tumor expression of TAZ, YAP, AMPK, SCD1, and HMGCR by immunohistochemistry in 65 Her2+ breast cancer patients who underwent trastuzumab-based neoadjuvant treatment. The aim of the study was to assess the impact of the immunohistochemical expression of the Hippo pathway transducers and cell metabolism regulators on pathological complete response. Low expression of cytoplasmic TAZ, both alone and in the context of a composite signature identified by machine learning including also low nuclear levels of YAP and HMGCR and high cytoplasmic levels of SCD1, was a predictor of residual disease in the univariate logistic regression. This finding was not confirmed in the multivariate model including estrogen receptor > 70% and body mass index > 20. However, our findings were concordant with overall survival data from the TCGA cohort. Our results, possibly affected by the relatively small sample size of this study population, deserve further investigation in adequately sized, ad hoc prospective studies

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available. Methods: We carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recruited. We primarily focused on treatment tolerability, with toxicity being reported as potential cause of treatment discontinuation. Secondarily, we assessed effectiveness in the overall study population and in a subset having a minimum follow-up of 2 years. Results: Overall, 270 patients were retrospectively identified. The 50.4% of the patients had residual node positive disease, 7.8% and 81.9% had large or G3 residual tumor, respectively, and 80.4% a Ki-67 >20%. Toxicity-related treatment discontinuation was observed only in 10.4% of the patients. In the whole population, at a median follow-up of 15 months, 2-year disease-free survival was 62%, 2 and 3-year overall survival 84.0% and 76.2%, respectively. In 129 patients with a median follow-up of 25 months, 2-year disease-free survival was 43.4%, 2 and 3-year overall survival 78.0% and 70.8%, respectively. Six or more cycles of capecitabine were associated with more favourable outcomes compared with less than six cycles. Conclusion: The CaRe study shows an unexpectedly good tolerance of adjuvant capecitabine in a real-world setting, although effectiveness appears to be lower than that observed in the CREATE-X study. Methodological differences between the two studies impose significant limits to comparability concerning effectiveness, and strongly invite further research

Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study

Background/Objectives: HER2-positive breast cancer (HER2+BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been established as the standard of care in the adjuvant setting for HER2+BC patients who do not obtain pCR. The ATD study aimed to evaluate the real-world tolerability of T-DM1 in this setting. The secondary objective was to assess the effectiveness. Methods: This was a multicenter, retrospective study across 24 Italian oncology centers, including 410 patients with HER2+BC treated with adjuvant T-DM1 following a lack of pCR after NAT. Patient characteristics, NAT regimens, and surgical outcomes were recorded. Tolerability was assessed by documenting adverse events (AEs) according to the CTCAE (v5.0). Preliminary effectiveness was evaluated in terms of relapse-free survival (RFS) and overall survival (OS). Results: Overall, 228 patients (55.6%) experienced at least one AE related to T-DM1, with 4.9% experiencing grade 3 or higher AEs. The most common AEs were hepatotoxicity (18.5%) and thrombocytopenia (17.6%). T-DM1 was discontinued in 10.0% of patients due to toxicity. After a median follow-up of 25 months, 31 relapse events (7.6%) and 22 deaths (5.4%) were reported. The preliminary incidence of RFS and OS events was similar between patients who completed the T-DM1 course and those who discontinued it early. Conclusions: T-DM1 demonstrated a manageable safety profile, and the adverse events were consistent with those reported in randomized trials. The data are not yet sufficient to allow for a formal analysis of RFS and OS, and long-term follow-up is required

The Influence of Local Governance: Effects on the Sustainability of Bioenergy Innovation

This paper deals with processes and outcomes of sustainable bioenergy development in Emilia Romagna. It draws on an on-going research project concerning inclusive innovation in forest-based bioenergy and biogas in Norway, Sweden, Finland and Italy. The goal is to explore how local governance impacts on inclusive innovation processes and triple bottom sustainability of bioenergy development in Emilia Romagna and, ultimately, to contribute to the debate on the bioeconomy. It thus compares the case of biogas and forest-based bioenergy production. The study adopts an analytical framework called Grounded Innovation (GRIP) and the local governance approach. The study uses qualitative methods and particularly semi-structured interviews and governance analysis. The key results show different outcomes on both inclusive innovation and triple bottom-line dimensions. Biogas has not fostered inclusiveness and triple bottom line sustainability benefits, contrary to forest-based bioenergy. The findings indicate that the minor role of local actors, particularly municipalities, in favour of industrial and national interests may jeopardise the sustainability of biobased industries. Besides, policies limited to financial incentives may lead to a land-acquisition rush, unforeseen local environmental effects and exacerbate conflicts.publishedVersio

The ADAM platform

&amp;lt;p&amp;gt;Operational Earth Observation (EO) satellite missions are entering their 5&amp;lt;sup&amp;gt;th&amp;lt;/sup&amp;gt; lifetime decade, and the need to access historical data has strongly increased, particularly for long-term science and environmental monitoring applications. This trend that drives users to request long time-series of data will increase even more in the future, in particular regarding the interest on global change assessment and monitoring to support policy makers decisions on atmosphere, ocean, cryosphere, carbon and other biogeochemical cycles safeguard.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;The Copernicus initiative (https://www.copernicus.eu) is playing a unique and unprecedented role form the point of view of amount, relevance and quality of provided environmental data. In the frame of the European Commission funded activities, the Data and Information Access Service (DIAS) are operated by five different consortia to acquire, process, archive and distribute data from Copernicus and Third-Party Missions.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;With this enormous availability of past, present, and future geospatial environmental data, there is the need to make users able to identify the datasets that best fit with their needs and obtain these data in fastest and easiest-to-use possible way. The Advanced geospatial DAta Management - ADAM platform (https://adamplatform.eu/) provides discovery, access, processing and visualization services for data in the distributed cloud environment, significantly reducing the burden of data usability.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;ADAM allows the exploitation of the content of EO data archives extended from a few years to decades and therefore makes their continuously increasing scientific value fully accessible. The advances in satellite sensor characteristics (spatial resolution, temporal frequency, spectral sensors) as well as in all related technical aspects (data and metadata format, storage, infrastructures) underline the strong need to preserve the EO space data without time constraints and to keep them accessible and exploitable, as they constitute a humankind asset. This is a typical big data challenge that ADAM can face. &amp;amp;#160;&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;This paper describes the ADAM platform and various application domains supported with its data science analytics and visualization capabilities.&amp;lt;/p&amp;gt; </jats:p